

A system for enhancing genome-wide coexpression dynamics study

Ker-Chau Li^{†*}, Ching-Ti Liu, Wei Sun, Shinsheng Yuan[†], and Tianwei Yu

Department of Statistics, 8125 Mathematical Sciences Building, University of California, Los Angeles, CA 90095-1554

Edited by Michael S. Waterman, University of Southern California, Los Angeles, CA, and approved August 30, 2004 (received for review April 28, 2004)

Statistical similarity analysis has been instrumental in elucidation of the voluminous microarray data. Genes with correlated expression profiles tend to be functionally associated. However, the majority of functionally associated genes turn out to be uncorrelated. One conceivable reason is that the expression of a gene can be sensitively dependent on the often-varying cellular state. The intrinsic state change has to be plastically accommodated by gene-regulatory mechanisms. To capture such dynamic coexpression between genes, a concept termed “liquid association” (LA) has been introduced recently. LA offers a scoring system to guide a genome-wide search for critical cellular players that may interfere with the coexpression of a pair of genes, thereby weakening their overall correlation. Although the LA method works in many cases, a direct extension to more than two genes is hindered by the “curse of dimensionality.” Here we introduce a strategy of finding an informative 2D projection to generalize LA for multiple genes. A web site is constructed that performs on-line LA computation for any user-specified group of genes. We apply this scoring system to study yeast protein complexes by using the *Saccharomyces cerevisiae* protein complexes database of the Munich Information Center for Protein Sequences. Human genes are also investigated by profiling of 60 cancer cell lines of the National Cancer Institute. In particular, our system links the expression of the Alzheimer’s disease hallmark gene *APP* (amyloid- β precursor protein) to the β -site-cleaving enzymes BACE and BACE2, the γ -site-cleaving enzymes presenilin 1 and 2, apolipoprotein E, and other Alzheimer’s disease-related genes.

microarray | gene expression | protein complex | *Saccharomyces cerevisiae* | Alzheimer’s disease

Microarray technologies enable simultaneous measurement of transcript abundance at the full-genome scale. The voluminous data generated under various conditions contain numerous messages about gene regulation and protein function. They are invaluable for deciphering the complex cellular circuitry. But the type of information distillable from a given expression database can vary substantially, depending on the computational/statistical/mathematical method applied (1–5). In this paper, we focus on a subtle pattern of coexpression that has become relatively easy to detect by means of the recently developed concept of “liquid association” (LA) (6).

Profile similarity is a concept underlying many microarray elucidation procedures. Consider a matrix with each row representing one gene and each column representing one condition. The j th value in the i th row shows the level of expression for gene i under condition j . The expression profile for a gene refers to the corresponding row in the matrix. Profile similarity can be measured by the correlation between two rows. It has been thought that genes with similar expression profiles are likely to be functionally associated. The encoded proteins may participate in the same pathway, form a common structural complex, or be regulated by the same mechanism.

Although coexpressed genes are likely to be functionally associated, the profiles of most functionally associated genes turn out to be uncorrelated. One reason is the high noise level of microarray data. Another explanation is that not all genes are regulated at the

mRNA level. Yet a third possibility can be described in terms of LA. This more advanced concept of statistical association originates from the need to describe a situation as schematized in Fig. 1 *Left*, wherein two opposing trends between X and Y are displayed. The positive and negative correlations cancel each other out, rendering the overall correlation insignificant. It would be valuable to learn why and how the change of trend occurs. But for real data, such hidden trends are not easy to detect directly from the scatterplot of X and Y . To alleviate the difficulty, we look for additional variables that may be associated with the change of the trend. LA quantifies how well a candidate variable Z can be used for this purpose. There are two types of change. A positive value of LA indicates the change from a negative to positive correlation as the value of Z increases. A negative value of LA indicates just the opposite way of changing, from a positive to negative correlation. The adjective “liquid,” as opposed to “solid” or “steady,” depicts this subtle pattern of association between X and Y .

Why is the LA suitable for describing subtle coexpression patterns? First, many genes have multiple functions and their biological roles may be dependent on the often-varying cellular state. Second, two proteins engaged in a common process under some conditions may disengage and embark on activities of their own under other conditions. This fact implies that both the strength and the pattern of association between the expression profiles of X and Y may vary as the intrinsic cellular state changes. Third, if the cellular state change is correlated with the expression of a third gene Z , then the correlation change may be detected by conditioning on Z . Fourth, because the relevant state variable is often unknown, to find out which genes can act as candidate for a mediator Z , a genome-wide search is appropriate. However, this search is an insurmountable challenge if inspection of the gene expression activity were to be done by direct examination of the scatterplots by eye. Yeast, for example, has >6,000 genes. The total number of triplets would be >36 billion. The situation is even worse for studying human genes. Consequently, an easy-to-compute index of how likely one is to find a LA pattern is desirable. After some mathematical derivation, a formula of LA was given by Li (6), which turns out to be simple enough to serve the purpose.

The Stanford cell-cycle database (<http://genome-www.stanford.edu/cellcycle>) was used to show how some subtle gene regulation patterns in yeast could be found only by the LA method. One example reveals how the enzymes associated with the urea cycle/arginine biosynthesis are expressed to ensure proper metabolite flow along this metabolic pathway. In particular, the expression profiles of $X = ARG2$ (acetylglutamate synthase) and $Y = CAR2$ (ornithine aminotransferase) are uncorrelated. But after a genome-wide search for the LA score leaders had been conducted for this pair, an enzyme adjacent in the pathway, *CPA2* (arginine-specific

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: LA, liquid association; PLA, projection-based LA; MIPS, Munich Information Center for Protein Sequences; SGD, *Saccharomyces Genome Database*; AD, Alzheimer’s disease; APP, amyloid- β precursor protein.

[†]The University of California, Los Angeles, has filed a patent application based on earlier published work by K.-C.L. and S.Y. on “liquid association” (6, 7).

^{*}To whom correspondence should be addressed. E-mail: kcli@stat.ucla.edu.

© 2004 by The National Academy of Sciences of the USA




Fig. 1. LA and PLA. (Left) Illustration of the concept of LA. X and Y are uncorrelated because the two opposing trends nullify each other. Low values of Z (green) are associated with the positive trend, whereas high values of Z (red) are associated with the negative trend. Z plays a mediator role. The LA score is negative in this case. For the gene expression application, each dot represents one condition under which the expression levels of genes X , Y , and Z are measured. (Right) Illustration of projection-based LA. The expression profiles for a group of p genes with n conditions can be viewed as n points in p -dimensional space; $p = 4$ is shown here with each blue axis representing one gene. High-dimensional data are difficult to visualize directly. Two projections (pink and yellow arrows) are sought so that the LA pattern can be revealed.

carbamoyl-phosphate synthase, large subunit), was found at the 8th place from the negative score end. The correlation between *ARG2* and *CAR2* changes from positive to negative as the expression of *CPA2* increases. This change of correlation reflects well a remarkable cellular control on the influx and efflux of ornithine in response to the arginine demand. The high level of *CPA2* indicates a cellular state ready for arginine biosynthesis. Under this state, we observe a negative correlation between *ARG2* and *CAR2*. Up-regulation of *ARG2* is concomitant with down-regulation of *CAR2*, thereby preventing the newly synthesized ornithine from leaving the urea cycle.

LA was further applied in a functional genomic study of the National Cancer Institute's anticancer drug screen (7). In all, 60 representative human cell lines from seven cancer types (lung, colon, melanoma, kidney, ovary, brain, and leukemia) were selected, and their responsiveness over a broad range of concentration for tens of thousands of anticancer compounds was tested. More recently, molecular characterization of these cell lines was made available by profiling thousands of genes with microarrays (http://dtp.nci.nih.gov/docs/cancer/cancer_data.html) (8–10). In correlating drug sensitivity profiles with gene expression, most drugs of known molecular mechanism turn out to be uncorrelated with their molecular-target genes. In ref. 7, LA is used to find candidate genes that intervene, confound, and weaken the drug–gene correlation.

The LA measure deals with only two genes. How to bypass this limitation in studies that involve multiple genes at one time? In this article, we take an informative low-dimension projection approach as schematized in Fig. 1 Right. First, the expressions of a group of p genes under n conditions are viewed as n points in a p -dimensional space. While we wish to visualize how the points are distributed, this is hard to do for $p > 3$. To sidestep the obstacle, a promising strategy is to project the data to a lower-dimensional space. The popular principal component analysis (PCA) uses the directions with the largest variance for projection. But because our goal is to reveal the LA pattern as clearly as possible after projection, we next develop a different formulation of informative projection.

Theory

Our theory is presented in terms of continuous random variables. Suppose all variables are standardized to have mean 0 and variance 1 so that the correlation between variables X and Y is equal to $E(XY)$. With the presence of a third variable Z , we denote the conditional expectation $E(XY|Z = z)$ by $g(z)$. The overall correlation between X and Y , $E(XY)$, is equal to $Eg(Z)$. We regard $g(z)$ as the coexpression measure between gene X and gene Y when gene Z is expressed at level z . The derivative $g'(z)$ quantifies how $g(z)$

varies as z increases. LA of X and Y with respect to Z is defined by $LA(X, Y|Z) = Eg'(Z)$. A simple estimate of LA is available under the normal assumption for Z : $LA(X, Y|Z) = E(XYZ)$. A normal score transformation on each gene profile is performed before analysis.

To extend LA for a group of p genes, let $\mathbf{X}$ denote a vector of p variables, $X_1, \dots, X_p$, where each variable measures the expression level of one gene. A one-dimensional projection of $\mathbf{X}$ is a linear combination $a'\mathbf{X} = a_1X_1 + \dots + a_pX_p$ with norm $\|a\| = 1$. For a 2D projection, we require that the two projection directions a, b be orthogonal to each other: $a'b = a_1b_1 + \dots + a_pb_p = 0$. After projection, the liquid association between $a'\mathbf{X}$ and $b'\mathbf{X}$ mediated by Z becomes

$$\begin{aligned} LA(a'\mathbf{X}, b'\mathbf{X}|Z) &= E(a'\mathbf{X}b'\mathbf{X}Z) \\ &= E(a'\mathbf{X}\mathbf{X}'bZ) = a'E(Z\mathbf{X}\mathbf{X}')b. \end{aligned}$$

The most informative 2D projection for revealing the LA pattern can be found by maximizing $|a'E(Z\mathbf{X}\mathbf{X}')b|$ over any pair of orthogonal projection directions a, b .

This maximization can be done by eigenvalue decomposition on $E(Z\mathbf{X}\mathbf{X}')$:

$$E(Z\mathbf{X}\mathbf{X}')v_i = \lambda_i v_i, \quad \lambda_1 \geq \dots \geq \lambda_p,$$

where v_i are eigenvectors and λ_i are eigenvalues. The following theorem conveys the final result. The proof is given later.

Theorem. Assume that Z is normal with mean 0 and standard deviation 1. Subject to $\|a\| = \|b\| = 1$ and the orthogonal condition $a'b = 0$, the maximum for the absolute value of $LA(a'\mathbf{X}, b'\mathbf{X}|Z)$ is equal to $(\lambda_1 - \lambda_p)/2$. The optimal 2D projection directions are given by $a = (v_1 + v_p)/\sqrt{2}$ (or $-a$), $b = (v_1 - v_p)/\sqrt{2}$ (or $-b$).

The proper signs of a and b are determined in the following way. Let $a_i^+ = \max\{a_i, 0\}$, $a^+ = (a_1^+, \dots, a_p^+)$ and let $a_i^- = \min\{a_i, 0\}$, $a^- = (a_1^-, \dots, a_p^-)$. If $\text{var}(a^+\mathbf{X}) \geq \text{var}(a^-\mathbf{X})$, set $\text{sign}(a) = 1$ and keep a as the first projection direction; otherwise set $\text{sign}(a) = -1$ and use $-a$ as the first projection direction. The sign of the second projection vector b is determined in the same way. The resulting liquid association is called the *projection-based liquid association* (PLA) for $\mathbf{X}$ mediated by Z and is denoted by $PLA(\mathbf{X}|Z)$.

Proof: By eigenvalue decomposition, we put $E(Z\mathbf{X}\mathbf{X}') = \lambda_1 v_1 v_1' + \dots + \lambda_p v_p v_p'$. Represent two candidate projection directions a, b as $a = c_1 v_1 + \dots + c_p v_p$, $b = d_1 v_1 + \dots + d_p v_p$ under the constraints

$$c_1^2 + \dots + c_p^2 = d_1^2 + \dots + d_p^2 = 1, \quad [1]$$

$$c_1 d_1 + \dots + c_p d_p = 0. \quad [2]$$

Because $LA(a'\mathbf{X}, b'\mathbf{X}|Z) = a'E(Z\mathbf{X}\mathbf{X}')b = c_1 d_1 \lambda_1 + \dots + c_p d_p \lambda_p$, we need to find the maximum of $|c_1 d_1 \lambda_1 + \dots + c_p d_p \lambda_p|$. Denote $\lambda(d) = d_1^2 \lambda_1 + \dots + d_p^2 \lambda_p$. Now, using constraint 2, we see that

$$\begin{aligned} |c_1 d_1 \lambda_1 + \dots + c_p d_p \lambda_p| &= |c_1 d_1 (\lambda_1 - \lambda(d)) + \dots + c_p d_p (\lambda_p - \lambda(d))| \\ &\leq \{d_1^2 (\lambda_1 - \lambda(d))^2 + \dots + d_p^2 (\lambda_p - \lambda(d))^2\}^{1/2} \text{ (by 1)} \end{aligned} \quad [3]$$

The last expression can be viewed as the standard deviation of a discrete random variable U with $P\{U = \lambda_i\} = d_i^2$, $i = 1, \dots, p$. To maximize the standard deviation, the probability mass has to be placed only on the endpoints λ_1, λ_p . Thus we have $d_1^2 = 1/2$, $d_2 = \dots = d_{p-1} = 0$, $d_p^2 = 1/2$. Without loss of generality, we take $d_1 = 1/\sqrt{2} = d_p$ and return to inequality 3. We need only to maximize $|c_1 - c_p|(\lambda_1 - \lambda_p)/\sqrt{2}$. Using Eq. 1, this can be achieved at $c_1 = \sqrt{2}$, $c_p = -\sqrt{2}$, $c_2 = \dots = c_{p-1} = 0$. This proves the theorem.

Method

To summarize what we have developed, for a group of p genes $\mathbf{X} = (X_1, \dots, X_p)'$ and a candidate mediator Z , the procedure of PLA comprises the following steps.

(i) Apply the normal score transformation to each gene profile.

(ii) For any two genes X_i, X_j in the group, compute the original LA score $L(X_i, X_j|Z) = (X_{i1}X_{j1}Z_1 + \dots + X_{im}X_{jm}Z_m)/m$, where m denotes the total number of conditions and X_{ik} denotes the expression of gene i under condition k .

(iii) Put the LA scores in a p by p matrix and use it to estimate $E(\mathbf{X}\mathbf{X}')$.

(iv) Conduct an eigenvalue decomposition on the matrix obtained in step iii to find the eigenvectors $v_1, \dots, v_p$ and eigenvalues $\lambda_1 \geq \dots \geq \lambda_p$.

(v) Let $a = [v_1 + v_p]/\sqrt{2}$ and $b = [v_1 - v_p]/\sqrt{2}$ and determine $\text{sign}(a)$, $\text{sign}(b)$ as in the discussion following the statement of the Theorem.

(vi) Set $\text{PLA}(\mathbf{X}|Z) = \text{sign}(a) \text{sign}(b)(\lambda_1 - \lambda_p)/2$.

We assess the statistical significance of the score $\text{PLA}(\mathbf{X}|Z)$ by comparing it to a reference distribution obtained by permutation. This reference distribution is given for each PLA output table in the supporting information. More precisely, for each group of genes $\mathbf{X}$ of interest, we generate a large number of artificial profiles Z^* by randomly permuting $(Z_1, \dots, Z_m)$. Then we evaluate each $\text{PLA}(\mathbf{X}|Z^*)$ and pool the results to form the reference distribution. As usual, the p value can be determined by counting how often $\text{PLA}(\mathbf{X}|Z^*)$ exceeds $\text{PLA}(\mathbf{X}|Z)$.

Results

Both yeast and human genes are studied. For yeast, we use protein complexes from the Saccharomyces cerevisiae-Protein Complexes database of the Munich Information Center for Protein Sequences (MIPS; <http://mips.gsf.de/proj/yeast/catalogues/complexes/index.html>). Two gene expression datasets are considered: the Stanford cell-cycle database (11) and a yeast segregation database generated by Brem *et al.* (12). For the human gene study, we use the cDNA gene expression database for the 60 cancer cell lines of the National Cancer Institute (8, 9).

Cytoplasmic Translation Initiation Complex eIF2. The Stanford cell-cycle data are used here. MIPS assigns three genes to this complex: *SUI2*, *SUI3*, and *GCD11*, encoding the α , β , and γ subunits of eukaryotic translation initiation factor eIF2. eIF2 acts by binding and delivering the initiator Met-tRNA_{Met} to the 40S ribosomal subunit in a GTP-dependent manner (13). The correlations between these three gene profiles are low: 0.37, 0.35, and 0.15, respectively, for (*GCD11*, *SUI3*), (*GCD11*, *SUI2*), and (*SUI2*, *SUI3*). Take them as $\mathbf{X}$ and apply PLA for a genome-wide search; the output is given in Table 1, which is published as supporting information on the PNAS web site. Among the top 20 genes with the best positive PLA scores, we find ribosome small subunits (*RPS26A*, and *RPS23A*), ribosome large subunit assembly and maintenance (*RPL11B*, *RPL10*, and *DBP10*), and rRNA processing genes (*IFH1*, and *DBP10*).

Fig. 3 Upper, which is published as supporting information on the PNAS web site, shows the optimal LA-projection as mediated by $Z = \text{RPS26A}$, whereas Fig. 3 Lower gives scatterplots between individual genes. A subtle coherent pattern of activation is revealed. When *RPS26A* is up-regulated (points coded in red triangles), we find high expression of *SUI3* from Fig. 3 Lower Right and a positive correlation between *GCD11* and *SUI2* from Fig. 3 Lower Left. When *RPS26A* is down-regulated (points coded in blue diamonds), the coherence dissolves.

TIF4631, TIF4632, and CAF20. Stanford cell-cycle data are used here. These three genes participate in translation initiation complex eIF4F. *TIF4631* and *TIF4632* encode two similar proteins, which




Fig. 2. Translation initiation complex eIF4F. (Upper) The optimal LA projection as mediated by *TIF5*. (Lower Left) Down-regulation of *TIF5* indicates weak *CAF20* activity. (Lower Right) A negative trend between *CAF20* and *TIF4631* is observed when *TIF5* is up-regulated, reflecting the antagonistic roles of *CAF20* and *TIF4631* in translation regulation.

play a positive pole in translation (14). They bind to the mRNA cap-binding protein CDC33p. In contrast, *CAF20*, which encodes a small protein, p20, is a negative regulator of translation. It represses cap-dependent translation initiation through the competitive binding to CDC33p (15). We applied PLA to this group. The result is given in Table 2, which is published as supporting information on the PNAS web site. The gene with best negative PLA score is *TIF5*, which encodes the translation initiation factor eIF5.

Antagonistic Pattern in *CAF20* and *TIF4631* Expression. A closer examination of the expression pattern between *TIF5*, *CAF20*, and *TIF4631* was undertaken. In Fig. 2 Lower Left, down-regulation of *TIF5* (points coded in blue diamonds) is concomitant with low expression of *CAF20*. The *TIF5*-encoded protein eIF5 is required for the joining of the 60S ribosome subunit with the preinitiation complex to begin the translation (16). When the expression of *TIF5* is low, cytoplasmic translation is likely to be less active. Cells do not express much *CAF20* because of nothing to repress. In contrast, when the *TIF5* expression is up (points coded in red color), a negative trend is visible between *TIF4631* and *CAF20* (Fig. 2 Lower Right). This result shows well the competitive roles between *CAF20* and *TIF4631* in translation initiation.

In addition to *TIF5*, the list of PLA score leaders includes *RPL30* (structural constituent of the ribosome), *YTM1* (microtubule-associated protein, ribosomal large subunit biogenesis), *PNO1*, and *RAP1*. *PNO1* encodes a component of the 90S preribosome, which is required for pre-18S rRNA processing (17). *RAP1* (repressor activator protein) is involved in diverse processes. In its role as a transcription activator, the largest group of target genes is those that encode ribosomal proteins (18).

Kinetochore Protein Complex. The yeast segregation data generated by Brem *et al.* (12) are used in this example. MIPS puts nine genes in this group (*CBF2*, *SKP1*, *CTF13*, *CEP3*, *CBF1*, *CSE4*, *MIF2*, *BIR1*, and *CBF5*). Accurate chromosome segregation depends on a specialized chromosomal structure, the kinetochore/centromere. *CBF2* is essential for chromosome segregation and movement of centromeres along microtubules. The *SKP1*, *CBF2*, *CTF13*, and *CEP3* products form a multisubunit complex, which binds to the CDEIII domain of the centromere. *CBF1* interacts with the CDEI domain of the centromere. *CSE4*, *MIF2*, and *BIR1* are also

involved in chromosome segregation. *CBF5* encodes a major low-affinity 55-kDa centromere/microtubule-binding protein. *CTF13* is excluded from analysis because its expression profile has >20% missing values. The correlations between genes in this group are mostly quite low (see Table 3, which is published as supporting information on the PNAS web site).

Table 4, which is published as supporting information on the PNAS web site, gives the PLA score leaders after the genome-wide search. Three leading genes, *SFI1*, *SPC72*, and *FIN1* are localized in spindle pole body. *SFI1* protein has conserved centrion-binding sites and an essential function in budding yeast spindle pole body duplication (19). *FIN1* protein forms cell cycle-specific filaments between spindle pole bodies (20). *SPC72* controls proper migration of the nucleus. It interacts with the microtubule-binding protein *STU2* and participates in mitotic chromosome segregation (21).

We turn to the gene with the best negative PLA score, *YFR044C* (*CNN1*). This gene encodes a kinetochore protein copurified with NNF1p [Saccharomyces Genome Database (SGD) annotation], but its molecular function is still unknown. In contrast, NNF1p is better understood. It is a spindle pole protein required for accurate chromosome segregation (22). The correlation between the expression profiles of *YFR044C* and NNF1 is weak (0.34). This finding prompted us to apply the regular LA analysis to this pair. The gene with the best positive LA score turns out to be *MSH3*, a gene with the second-best positive score in the earlier PLA result given in Table 4. *MSH3* protein forms a complex with *MSH2* protein, which is active in mismatch repair and recombination (23). Interestingly, the gene that has the highest correlation (0.77) with *MSH2* is *STU2*, and the binding partner of *SPC72* is discussed earlier.

AP-1 Complex. The yeast segregation data are used. The AP-1 complex is a heterotetramer composed of two large subunits (APL2 and APL4), one medium subunit (APM1), and one small subunit (APS1). Clathrin-coated vesicles budding from the trans-Golgi network interact with AP-1 complex. The correlations among these four genes are low (see Table 5, which is published as supporting information on the PNAS web site). The output of applying PLA is given in Table 6, which is published as supporting information on the PNAS web site. Leading on the positive-score side is *ENT4*. The *ENT4* protein contains the epsin N-terminal homology (ENTH) domain, which is essential in clathrin-dependent endocytosis (24). To help the study of other genes in the output, we submitted them to the Gene Ontology Term Finder in SGD for an automatic analysis. From the enriched terms in branch of the biological process, we found *END3* (endocytosis, polar budding), *SSO1* (Golgi to plasma membrane transport; nonselective vesicle fusion), *CHS5* (Golgi to plasma membrane transport, spore-wall assembly), *BUD7* (bud site selection; clathrin-coated vesicle); *SEC61* (protein–endoplasmic reticulum targeting), *SRP54* (protein–endoplasmic reticulum targeting), *APL2*, and *ENT4*.

Other Complexes. We have constructed a web site (<http://kiefner.stat.ucla.edu/LAP>) that gives the standard correlation and PLA results for each complex listed in the *Saccharomyces cerevisiae*-Protein Complexes database of MIPS. Researchers can quickly browse the results for the complex of interest to them. A gene ontology (GO) term summary table is provided for the output genes along with clickable buttons for submitting to GO term Finder of SGD. For instance, the SPB (spindle pole body) component complex_205 consists of 16 genes. Using Stanford cell cycle data, we remove two genes because of abundant missing values. The rest of them are used as a group for PLA application. The GO analysis on the 20 genes with the best negative PLA scores shows 7 genes in “cell proliferation” ($P = 0.00065$). Among them, five genes are in “cell cycle”: *SWI5*, *CDC39*, *SET3*, *SNT1*, and *CLB2*.

As another example, GO term Finder shows that the PLA output for the translation elongation eEF1 complex_225 (consisting of six genes) has nine genes in the cellular component “ribosome” (P

value 0.00002). They are *RPL9B*, *RPL21A*, *RPS9B*, *CDC19*, *RPL23A*, *RPS23B*, *RPS11B*, *RPS6B*, and *RPL14B*.

Genetic Markers. In the yeast segregation experiment by Brem *et al.* (12), the genetic marker profiles were also available. There are in total 3,312 markers, which cover >99% of the genome. A marker profile keeps track of the parental strains from which each of the 40 offspring inherits the marker. Our web site allows for treating them as *Z* and applying the same procedure as described in *Method* to compute the PLA scores. For instance, use the translation elongation eEF1 complex as *X* and specify the genetic marker files as *Z*. From the PLA output given in Table 7, which is published as supporting information on the PNAS web site, we find two markers located at genes *RPL28* and *RPL24B* that function as ribosome structural constituents and another two markers located at two genes participating in ribosome biogenesis: *NSA1* (constituent of 66S preribosomal particle, involved in 60S ribosomal unit biogenesis) and *MTR3* (35S primary transcript processing). Because marker profiles are highly correlated with the chromosome positions of the markers, many neighboring markers appear in Table 7. *RPL28* and *NSA1* fall within a block of four markers, *YGL101W*, *YGL103W* (*RPL28*), *YGL110C*, and *YGL111W* (*NSA1*), whereas *RPL24B* and *MTR3* embrace a block of five markers: *YGR148C* (*RPL24B*), *YGR149W*, *YGR150C*, *YGR157W*, *YGR158C* (*MTR3*). According to both MIPS and SGD, a *MTR3* mutant strain has defects in rRNA synthesis/processing. For our data, *MTR3* is the gene having the third-strongest negative correlation with the *MTR3* marker profile; see Table 8, which is published as supporting information on the PNAS web site.

Tumor Suppressor p53. The well known human tumor suppressor p53 is encoded by the gene *TP53*. A keyword query on *TP53* produces four hits in our database: *TP53*, *TP53INP1* (p53-inducible nuclear protein), *TPBP1* (p53-binding protein 1), and *TPBP2* (p53-binding protein 2). The correlations between these genes are low, falling between -0.0805 and 0.1904 . We applied PLA to this group; see the output Table 9, which is published as supporting information on the PNAS web site. We found *SMARCA4* (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4) at fourth place on the negative score side. The p value is far below 0.1%. The coefficients for the two projection directions are 0.97, 0.045, -0.015 , and 0.236, and -0.090 , 0.722, 0.629, and 0.2716, respectively. Because the weights on *TPBP2* (0.236 and 0.2716) are the lowest, we drop it from the group and apply PLA again to the three remaining genes. We find *SMARCA4* at the first place. By using genetic and biochemical approaches, *SMARCA4* was shown to interact with tumor suppressor p53; SWI/SNF complex is necessary for the activation of p53-mediated transcription (25).

Alzheimer's Disease (AD) Genes. Amyloid- β peptide is the predominant component of senile plaques in the brains of patients with AD. It is derived from the amyloid- β precursor protein (APP) by the consecutive proteolytic cleavage by β -secretase at the N terminus and by γ -secretase at the C terminus. APP is a widely expressed cell surface protein. Its normal role was linked to the control of gene expression in ref. 26, where the C-terminal intracellular fragment of APP was found to interact with the nuclear adaptor protein Fe65 (encoded by *APBB1*) and the histone acetyltransferase Tip60 (encoded by *HTATIP*). We compared the profiles of *APBB1* and *HTATIP* with the profile of *APP* and found that the correlations (-0.06 and -0.27 , respectively) are quite low. In search of genes that may play a role in weakening the correlation, we first applied the ordinary LA to the pair *APP* and *PBB1*. We found a β -site APP-cleaving enzyme BACE2 from the best 20 genes with negative LA scores; see Table 10, which is published as supporting information on the PNAS web site. We then applied LA again to the pair *APP* and *HTATIP*. This time we found a major component of

X, two gene profiles as Y, and 9,706 gene profiles (cell-line data) as Z. For the eigenvalue decomposition, we use C functions from Numerical Recipe (36) and integrate them into MySQL and PHP. For a query on a yeast complex with 25 genes, it takes less than 1 min to evaluate all PLA scores and find the PLA-score-leading genes.

One issue that merits further investigation is the biological relevance of other genes with equally high PLA scores, which we did not discuss. Recall that the assumption behind our method is the existence of a hidden cellular state that governs the coexpression of a group of genes under study. In each example, we reported a selective set of genes whose activities best represent the hidden cellular state, given the current limited knowledge on gene functions. In Tables 17–22, which are published as supporting information on the PNAS web site, we show that the majority of other unreported genes are likely to be coregulated in response to the same cellular state change characterized by the reported genes. In the case of cytoplasmic translation initiation complex eIF2, we have reported six genes (*RPS26A*, *RPS23A*, *RPL11B*, *RPL10*, *DBP10*, and *IFH1*) involved in the making of cytoplasmic ribosome. Two unreported genes, *TGS1* and *ARC1*, also have apparent roles associated with the translation mechanism. *ARC1* participates in tRNA aminoacylation for protein translation and in exporting tRNA from nucleus to cytoplasm. *TGS1* (small nuclear RNA/small nucleolar RNA cap hypermethylase) plays a role in the maturation of pre-mRNAs and pre-rRNA (37). Thus collectively, up-or-down regulation of these eight genes may point to a cellular state change about the rate of translation activity. The rest of the genes in Table 1 are either unknown or functionally diverse. However, we find a broadly consistent pattern of correlation between them and the eight representative genes; see Table 17. This correlation suggests that many of these genes are likely to be coregulated in response to the cellular state change. For example, *COG2* (endoplasmic reticulum-to-Golgi transport, intra-Golgi trans-

port, retrograde transport; protein binding), and *ARL1* (protein-vacuolar targeting) may be indicative of the supportive mechanism required immediately after translation. Indeed, genetic interaction studies have shown that continued functioning of the secretory pathway is essential for ribosome synthesis (38, 39). Tables 18–20 provide similar results for the other three yeast complexes.

For the p53 group, in addition to *SMARCA4*, we find four other genes, *CAV1*, *NRG1*, *PDCD2*, and *CITED2*, from Table 9. The correlation between these genes and others shows a consistent pattern of coregulation (Table 21). *CAV1* (caveolin-1) mediates cell cycle arrest through a p53/p21-dependent pathway (40). *NRG1* (neuregulin 1) activates a p53-dependent pathway in cancer cells (41). The human programmed cell death-2 (*PDCD2*) gene is a target of BCL6 repression (42), whereas the disruption of the p53 pathway affects the development of BCL6-expressing B cell lymphomas (43). *CITED2* encodes a CBP-p300-interacting transactivator, and CBP-p300 is involved in mediating p53 degradation (44).

For the AD gene group, Table 22 shows a consistent pattern of coregulation for *BACE2*, *CTSB*, *APOD*, *RAB1A*, and *GAB2* with other genes. *GAB2*, encoding a GRB2-associated binding protein, is included because Russo *et al.* (45) showed that in human brain, tyrosine-phosphorylated C-terminal fragments of APP form stable complexes with the adaptor proteins ShcA and GRB2. Three genes, *SNX9*, *ADAM9*, and *ADAM15*, from Tables 13, 14, and 16, respectively, are also noteworthy. Sorting nexin-9 (*SNX9*) interacts with the cytoplasmic domains of metalloprotease disintegrins *ADAM9* and *ADAM15* (46). Recently, Asai *et al.* (47) determined that *ADAM9* displays the APP α -secretase activity.

This work was funded in part by National Science Foundation Grants 0104038 and 0201005.

- Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 14863–14868.
- Tamayo, P., Slonim, D., Mesirov, J., Zhu, Q., Kitareewan, S., Dmitrovsky, E., Lander, E. S. & Golub, T. R. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 2907–2912.
- Alter, O., Brown, P. O. & Botstein, D. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 10101–10106.
- Marcotte, E. M., Pellegrini, M., Thompson, M. J., Yeates, T. O. & Eisenberg, D. (1999) *Nature* **402**, 83–86.
- Zhou, X., Kao, M. C. & Wong, W. H. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 12783–12788.
- Li, K.-C. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 16875–16880.
- Li, K.-C. & Yuan, S. (2004) *Pharmacogenomics J.* **4**, 127–135.
- Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C. R., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., *et al.* (2000) *Nat. Genet.* **24**, 227–235.
- Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, M. D., *et al.* (2000) *Nat. Genet.* **24**, 236–244.
- Staunton, J. E., Slonim, D. K., Coller, H. A., Tamayo, P., Angelo, M. J., Park, J., Scherf, U., Lee, J. K., Reinhold, W. O., Weinstein, J. N., *et al.* (2001) *Proc. Natl. Acad. Sci. USA* **98**, 10787–10792.
- Spellman, T. P., Sherlock, G., Zhang, Q. M., Iyer, R. V., Anders, K., Eisen, M. B., Brown, O. P., Botstein, D. & Futcher, B. (1998) *Mol. Biol. Cell* **9**, 3273–3297.
- Brem, R., Yvert, G., Clinton, R. & Kruglyak, L. (2002) *Science* **296**, 752–755.
- Nika, J., Rippel, S. & Hannig, E. M. (2001) *J. Biol. Chem.* **276**, 1051–1056.
- Ramirez, C. V., Vilela, C., Berthelot, K. & McCarthy, J. E. (2002) *J. Mol. Biol.* **318**, 951–962.
- Ptushkina, M., von der Haar, T., Vasilescu, S., Frank, R., Birkenhäger, R. & McCarthy, E. G. J. (1998) *EMBO J.* **17**, 4798–4808.
- Das, S. & Maitra, U. (2001) *Prog. Nucleic Acid Res. Mol. Biol.* **70**, 207–231.
- Senapin, S., Clark-Walker, G. D., Chen, X. J., Seraphin, B. & Daugeron, M. C. (2003) *Nucleic Acids Res.* **31**, 2524–2533.
- Lieb, J. D., Liu, X., Botstein, D. & Brown, P. O. (2001) *Nat. Genet.* **28**, 327–334, and erratum (2001) **29**, 100.
- Kilmartin, J. V. (2003) *J. Cell Biol.* **162**, 1211–1221.
- van Hemert, M. J., Deelder, A. M., Molenaar, C., Steensma, H. Y. & van Heusden, G. P. (2003) *J. Biol. Chem.* **278**, 15049–15055.
- Usui, T., Maekawa, H., Pereira, G. & Schiebel, E. (2003) *EMBO J.* **22**, 4779–4793.
- Euskirchen, G. M. (2002) *Eukaryot. Cell* **1**, 229–240.
- Saparbav, M., Prakash, L. & Prakash, S. (1996) *Genetics* **142**, 727–736.
- Wendland, B., Steece, K. E. & Emr, S. D. (1999) *EMBO J.* **18**, 4383–4393.
- Lee, D., Kim, J. W., Seo, T., Hwang, S. G., Choi, E. J. & Choe, J. (2002) *J. Biol. Chem.* **277**, 22330–22337.
- Cao, X. & Südhof, T. C. (2001) *Science* **293**, 115–120, and erratum (2001) **293**, 1436.
- Thomas, E. A., Laws, S. M., Sutcliffe, J. G., Harper, C., Dean, B., McClean, C., Masters, C., Lautenschlager, N., Gandy, S. E. & Martins, R. N. (2003) *Biol. Psychiatry* **54**, 136–141.
- Rodriguez, R. N. (1982) in *Encyclopedia of Statistical Sciences*, eds. Kotz, S. & Johnson, N. L. (Wiley, New York), Vol. 2, pp. 193–204.
- Hubert, P. (1985) *Ann. Stat.* **13**, 435–526.
- He, H., von der Haar, T., Singh, C. R., Li, M., Li, B., Hinnebusch, A. G., McCarthy, J. E. & Asano, K. (2003) *Mol. Cell. Biol.* **23**, 5431–5445.
- Selkoe, D. J. (2001) *Physiol. Rev.* **81**, 741–766.
- Komano, H., Shiraiishi, H., Kawamura, Y., Sai, X., Suzuki, R., Serneels, L., Kawauchi, M., Kitamura, T. & Yanagisawa, K. (2002) *J. Biol. Chem.* **277**, 39627–39633.
- Phiel, C. J., Wilson, C. A., Lee, V. M. & Klein, P. S. (2003) *Nature* **423**, 435–439.
- Axmark, D., Widenius, M. M., Cole, J. & DuBois, P. (1997) *MySQL Reference Manual* (MySQL, Uppsala).
- Sklar, D. & Trachtenberg, A. (2003) *PHP Cookbook* (O'Reilly, Sebastopol, CA).
- Press, H. W., Teukolsky, A. S., Vetterling, T. W. & Flannery, P. B. (2002) *Numerical Recipes in C* (Cambridge Univ. Press, New York), 2nd Ed.
- Mouaikel, J., Bujnicki, J., Tazi, J. & Bordonne, R. (2003) *Nucleic Acids Res.* **31**, 4899–4909.
- Mizuta, K. & Warner, J. R. (1994) *Mol. Cell. Biol.* **14**, 2493–2502.
- Miyoshi, K., Miyakawa, T. & Mizuta, K. (2001) *Nucleic Acids Res.* **29**, 3297–3303.
- Galbiati, F., Volonte, D., Liu, J., Capozza, F., Frank, P. G., Zhu, L., Pestell, R. G. & Lisanti, M. P. (2001) *Mol. Biol. Cell* **12**, 2229–2244.
- Bacus, S. S., Yarden, Y., Oren, M., Chin, D. M., Lyass, L., Zelnick, C. R., Kazarov, A., Toyofuku, W., Gray-Bablin, J., Beerli, R. R., *et al.* (1996) *Oncogene* **12**, 2535–2547.
- Baron, B. W., Anastasi, J., Thirman, M. J., Furukawa, Y., Fears, S., Kim, D. C., Simone, F., Birkenbach, M., Montag, A., Sadhu, A., Zeleznik-Le, N. & McKeithan, T. W. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 2860–2865.
- Kusam, S., Vasanwala, F. H. & Dent, A. L. (2004) *Oncogene* **23**, 839–844.
- Matt, T., Martinez-Yamout, M. A., Dyson, H. J. & Wright, P. E. (2004) *Biochem. J.* **381**, 685–691.
- Russo, C., Dolcini, V., Salis, S., Venezia, V., Zambrano, N., Russo, T. & Schettini, G. (2002) *J. Biol. Chem.* **277**, 35282–35288.
- Howard, L., Nelson, K. K., Maciewicz, R. A. & Blobel, C. P. (1999) *J. Biol. Chem.* **274**, 31693–31699.
- Asai, M., Hattori, C., Szabo, B., Sasagawa, N., Maruyama, K., Tanuma, S. & Ishiura, S. (2003) *Biochem. Biophys. Res. Commun.* **301**, 231–235.
- Stein, C. (1981) *Ann. Stat.* **9**, 1135–1151.